文献速递泌尿男性生殖肿瘤

迈向更相称的欧盟低干预临床试验框架:英国与瑞士的经验教训

Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland.
PubMed 文献 · Eur J Cancer · 2026-10-02

本文通过比较法律与政策分析,考察欧盟、英国和瑞士的低风险临床试验框架,识别各法域判定低风险试验的关键要素及监管后果,并以EORTC 2238「DE-ESCALATE」前列腺癌试验为例说明欧盟与瑞士框架差异带来的时间、成本和审查负担。文章建议欧盟改革应明确低干预试验定义并匹配相称的监管后果。

要点

  • 欧盟低干预认定依赖产品授权、证据支持与最小额外程序风险,对既定临床实践角色界定不如英瑞明确。
  • 英国提供通知制路径,瑞士对符合条件的A类试验豁免Swissmedic授权。
  • DE-ESCALATE案例显示欧盟与瑞士框架差异导致时间线、成本和审查负担不同。

核心结论

  • 欧盟应通过明确可接受证据和认可基于背景的既定临床实践来澄清低干预临床试验定义。
  • 低干预分类应产生相称的监管后果,包括加速通知路径及适当时以伦理委员会批准为中心的审查。

研究设计与样本

  • 对欧盟、英国和瑞士适用的低风险临床试验框架进行比较法律与政策分析。
  • 分析文本为截至2026年9月已生效或拟议的版本。
  • 以EORTC 2238「DE-ESCALATE」前列腺癌试验为案例说明欧盟与瑞士低风险框架差异。

主要发现

  • 欧盟低干预状态取决于产品授权、证据支持和最小额外程序风险,既定临床实践角色界定不如英瑞明确。
  • 英国提供通知制路径,瑞士对符合条件的A类试验豁免Swissmedic授权。
  • DE-ESCALATE案例说明框架差异导致时间线、成本和审查负担不同。

临床怎么用

  • 在欧盟开展上市后治疗优化试验时,需评估产品授权、证据支持与额外程序风险以判断是否符合低干预资格。
  • 多国学术研究可参考英国通知制或瑞士A类豁免路径设计监管策略。

局限性

  • 分析文本截至2026年9月已生效或拟议版本,后续法规变化可能影响结论。
  • 比较分析限于欧盟、英国和瑞士三个法域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Post-marketing treatment-optimisation trials evaluate established therapies to determine their optimal dosage, duration, sequencing, scheduling, and use in combination strategies. Although these studies may qualify as low-intervention clinical trials and generally entail lower additional risks than pre-authorisation drug-development trials, the current EU framework for these trials entails disproportionate regulatory requirements that may impede their conduct, particularly in multinational academic research that aims to improve patient-relevant outcomes, including quality of life, rather than to support the development or registration of new medicinal products. MATERIALS AND METHODS: This article undertakes a comparative legal and policy analysis of the low-risk clinical trial frameworks applicable in the European Union (EU), United Kingdom (UK), and Switzerland (CH). It identifies the principal elements within the legal provisions of each jurisdiction that determine whether a clinical trial may be categorised as low-risk and examines the regulatory implications that follow from such classification. More practically, the EU and CH low-risk framework divergencies are highlighted in the EORTC 2238 'DE-ESCALATE' prostate cancer trial case study. Texts were analysed as in force or proposed in September 2026. RESULTS: In the EU, low-intervention status depends on product authorisation, evidentiary support, and minimal added procedural risk, while leaving the role of established clinical practice less explicitly defined than in the UK and CH frameworks. The UK also provides a notification-based route, and CH exempts qualifying Category A trials from Swissmedic authorisation. DE-ESCALATE illustrates the resulting differences in timelines, costs, and review burdens. DISCUSSION: EU reform should clarify the low-intervention clinical trial definition by specifying acceptable evidence and recognising context-based established clinical practice. Classification should also produce proportionate regulatory consequences, including an accelerated notification pathway and, where appropriate, review centred on Ethics Committee approval.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kassas R, Lacombe D, Kromar S, et al. Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland. Eur J Cancer. 2026. PMID: 42833138. doi:10.1016/j.ejca.2026.117762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。